246 related articles for article (PubMed ID: 12385678)
1. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycillin/clavulanate.
File TM; Jacobs MR; Poole MD; Wynne B;
Int J Antimicrob Agents; 2002 Oct; 20(4):235-47. PubMed ID: 12385678
[TBL] [Abstract][Full Text] [Related]
2. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
Garau J
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults.
Petitpretz P; Chidiac C; Soriano F; Garau J; Stevenson K; Rouffiac E;
Int J Antimicrob Agents; 2002 Aug; 20(2):119-29. PubMed ID: 12297361
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
[TBL] [Abstract][Full Text] [Related]
5. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on amoxicillin/clavulanic acid 2000 mg/125 mg extended release (XR) in respiratory tract infections in adults.
McCormack PL; Keating GM
Treat Respir Med; 2005; 4(5):361-2. PubMed ID: 16137193
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetically enhanced amoxicillin/clavulanate (2,000/125 mg) in acute bacterial rhinosinusitis caused by Streptococcus pneumoniae, including penicillin-resistant strains.
Anon JB; Ferguson B; Twynholm M; Wynne B; Berkowitz E; Poole MD
Ear Nose Throat J; 2006 Aug; 85(8):500, 502, 504 passim. PubMed ID: 16999056
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
10. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
Jacobs MR
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
[TBL] [Abstract][Full Text] [Related]
12. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.
Sethi S; Breton J; Wynne B
Antimicrob Agents Chemother; 2005 Jan; 49(1):153-60. PubMed ID: 15616290
[TBL] [Abstract][Full Text] [Related]
14. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
Berry V; Hoover J; Singley C; Woodnutt G
Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
[TBL] [Abstract][Full Text] [Related]
15. Proof of concept: performance testing in models.
Craig WA
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
[TBL] [Abstract][Full Text] [Related]
16. A comparison of cefditoren pivoxil and amoxicillin/ clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study.
Fogarty CM; Cyganowski M; Palo WA; Hom RC; Craig WA
Clin Ther; 2002 Nov; 24(11):1854-70. PubMed ID: 12501879
[TBL] [Abstract][Full Text] [Related]
17. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia.
Higuera F; Hidalgo H; Feris J; Giguere G; Collins JJ
J Antimicrob Chemother; 1996 Mar; 37(3):555-64. PubMed ID: 9182112
[TBL] [Abstract][Full Text] [Related]
18. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
Easton J; Noble S; Perry CM
Drugs; 2003; 63(3):311-40. PubMed ID: 12534334
[TBL] [Abstract][Full Text] [Related]
19. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome.
Hoepelman IM; Möllers MJ; van Schie MH; Greefhorst AP; Schlösser NJ; Sinninghe Damsté EJ; van de Moosdijk CN; Dalinghaus WH; Eland ME; Mol SJ; Rozenberg-Arska M
Int J Antimicrob Agents; 1997 Jan; 9(3):141-6. PubMed ID: 9552709
[TBL] [Abstract][Full Text] [Related]
20. Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults.
McCormack PL; Keating GM
Drugs; 2005; 65(1):121-36. PubMed ID: 15610061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
